QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of ...

Core News & Articles

Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces ...

Core News & Articles

Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company d...

 rapport-reports-promising-epilepsy-study-outcomes-plans-phase-3-trials-next-year

Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety pr...

Core News & Articles

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price ta...

Core News & Articles

RAPP: 176% | Rapport Therapeutics' Phase 2a Trial Of RAP-219 In Drug-Resistant Focal Onset Seizures Met Its Primary Endpoin...

Core News & Articles

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients a...

Core News & Articles

Rapport Therapeutics, Inc.

Core News & Articles

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION